Evidence map›Paper›PMID 38259071›Full record

ArticleJournal of clinical microbiology2024

A genetic variant of

Mengqi Luo, Chao Dong, Xinghe Liang, Rong Na, Bin Zhou, Jinlin Hou, De-Ke Jiang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mengqi Luo *State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University , Guangzhou, China.ORCID 0000-0003-3161-4016
Chao Dong *School of Basic Medicine, Inner Mongolia Medical University , Hohhot, China.
Xinghe Liang *State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University , Guangzhou, China.
Rong NaDivision of Urology, Queen Mary Hospital, The University of Hong Kong , Hong Kong, China.
Bin ZhouState Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University , Guangzhou, China.
Jinlin HouState Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University , Guangzhou, China.ORCID 0000-0001-8230-8583
De-Ke JiangState Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University , Guangzhou, China.ORCID 0000-0002-7888-2344
Nanfang Hospital · CNInner Mongolia Medical University · CNQueen Mary Hospital · CN

Funding

MOST | National Key Research and Development Program of China (NKPs) 2022YFC2303600
6 · The paper itself

Abstract

Chemokine receptor 4 (CXCR4) plays a vital role in immunoregulation during hepatitis B virus (HBV) infection. This study aimed to screen single-nucleotide polymorphisms (SNPs) of

Indexed as

Hepatitis BHepatitis B, ChronicAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansInterferon-alphaPolyethylene GlycolsReceptors, CXCR4Recombinant ProteinsRetrospective StudiesTreatment OutcomeAntiviral AgentsCXCR4 protein, humanDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensInterferon-alphaPolyethylene GlycolsReceptors, CXCR4Recombinant Proteinschemokine receptor 4 (CXCR4)chronic hepatitis B (CHB)hepatitis B virus (HBV)pegylated interferon-alpha (PegIFNα)single-nucleotide polymorphism (SNP)

Identifiers

PMID38259071
PMCPMC10865838
OpenAlexW4391135863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.